BRKB 28
Alternative Names: BRKB-28Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator BrickBio
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Breast cancer; Gastric cancer
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
- 28 Dec 2024 No recent reports of development identified for preclinical development in Gastric-cancer in USA (Parenteral)